AQP4 antibody-positive NMOSD

Early use of immunosuppressive therapy — when compared with a later treatment start — was associated with fewer relapses and reduced disability among neuromyelitis optica spectrum disorder (NMOSD) patients with self-reactive antibodies against the AQP4 protein, a study from China showed. The data demonstrated a time-dependent treatment efficacy, with…

About half of neuromyelitis optica spectrum disorder (NMOSD) patients who test positive for self-reactive antibodies, or autoantibodies, against the AQP4 protein — a hallmark of the autoimmune disease — have at least one other type of autoantibody, according to a new study from South Korea. Many of these other…

The U.S. Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvz) to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against the aquaporin-4 (AQP4) protein. About 75% of people with NMOSD produce antibodies that bind to AQP4, according to the therapy’s developer, Alexion…

Ultomiris (ravulizumab) is now approved in Canada to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against aquaporin-4 (AQP4). According to a press release from Alexion Canada, which will market Ultomiris in the country, it’s the “first and only” long-acting therapy…

Genetic variations linked with cold sores and shingles infections have been associated with the development of AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), according to genetic analysis. The findings suggest that the herpes simplex virus, which is the cause of cold sores, and the varicella-zoster virus, which leads to…